Inflammatory disease drug developer Inflazome, based on research at University of Queensland and Trinity College Dublin, has added $45.6m in series B capital to its coffers.

Vrije Universiteit Brussel’s Camel-IDS collected funding from investors including Novo for a radiation-based oncology platform that will initially target Her2-positive brain metastatic breast cancer.

Memory technology supplier and New York University spinout Spin Memory has secured $52m in a round featuring Applied Ventures and Arm.

Bristol Myers-Squibb, Merck Group and Novo all took part in a $90m series C round for Galecto Biotech, which is commercialising research from Lund and Edinburgh universities.

Ohio Innovation Fund has returned to support a first series B tranche for Enable Injections, which is targeting a $50m final close.

Johnson & Johnson was among the investors in a $54.5m series A round for CuraSen Therapeutics, which is commercialising research from Stanford University.

Oxford Nanopore has secured $66m from Amgen, after the latter’s subsidiary Decode Genetics used the spinout’s technology to sequence hundreds of human genomes.

The cell biology technology developer, based on UC Berkeley research, took its total funding to almost $220m in a Nikon-led round that included fellow strategic backer Varian.

The Rockefeller spinout will use the series C proceeds to advance two cancer drug candidates through early-stage clinical trials.

Johns Hopkins oncology diagnostics spinout PGDx had previously raised approximately $99m.